Background: Inhibitors of the Na / H -exchanger (NHE1) and of angiotensin-converting enzyme (ACE) have been shown to reduce short-term (,6 h) tachycardia-induced atrial electrical remodeling. The role of NHE1 and ACE in longer-term electrical remodeling, as might occur with persistent AF, has not been studied. Methods: Dogs were subjected to atrial-tachypacing (400 bpm) for 7 days during treatment with 240 mg / day (standard clinical dose) of the NHE1 inhibitor cariporide (CariL, n56), 1000 mg / day cariporide (CariH, n56), 2 mg / kg / day of the ACE inhibitor enalapril (E, n56), or no-drug controls (n57). To ensure steady state concentrations at the onset of pacing, treatment began 3 days before the initiation of atrial tachypacing. Results were compared to those of unpaced dogs (n59). Results: Atrial tachypacing reduced atrial effective refractory period (ERP), e.g. at a basic cycle length of 300 ms from 12664 ms (unpaced, mean6S.E.) to 7968 ms (no-drug controls, P,0.001). ERP abbreviation was unchanged by CariL (8368 ms), CariH (8067 ms), or E (7665 ms). Atrial tachypacing increased mean duration of the longest AF episode in each dog (DAF) from 130680 s (unpaced) similarly in all groups: 8646364 s, no-drug controls; 6096376 s, CariL; 7096353 s, CariH; 6456365 s, E (P5NS for differences among groups). Sustained AF requiring cardioversion for termination was induced in 0% of unpaced dogs vs. 33% of CariL, 33% of CariH, 33% of E, and 43% of control dogs. AF inducibility by single extrastimuli increased from 462% in unpaced dogs to 48613% (P,0.01) in no-drug control dogs, an effect not changed by CariL (33614%), CariH (35617%) or E (48616%). Conclusions: In contrast to short-term (several-hour) atrial tachycardia-induced remodeling, remodeling by 7-day tachycardia is not affected by NHE1 or ACE inhibition. These results support the notion that short-term atrial tachycardia remodeling involves different mechanisms from longer-term remodeling, and urges caution in extrapolating results from studies of short-term remodeling to effects in longer-term remodeling as often occurs clinically.
Introduction
a variety of electrophysiological alterations, including atrial effective refractory period (ERP) abbreviation, that Atrial fibrillation (AF) is currently the most common promote AF inducibility and maintenance [1] [2] [3] [4] [5] . There is 21 sustained arrhythmia in clinical practice. It has been shown evidence for Ca overload as an initiating signal for that AF alters atrial electrophysiology to promote its own tachycardia-induced remodeling [6] [7] [8] [9] . maintenance, a process often referred to as electrophysioBecause of the limitations of presently available therapy, logical remodeling [1] . Sustained atrial tachycardia causes there has been an interest in developing novel approaches to AF therapy. One potentially interesting possibility is the use of drugs to prevent atrial electrical remodeling. The 21 T-type Ca -channel blocker mibefradil strongly inhibits atrial tachycardia-induced remodeling [10, 11] , but has 2. Methods been withdrawn from the market because of adverse drug 21 reactions. Although L-type Ca -channel blockers reduce 2.1. Animal preparation short-term atrial tachycardia remodeling (,24 h), they are ineffective for remodeling by longer-lasting atrial tachAll animal-handling procedures were approved by the ycardias [11, 12] .
animal research ethics committee of the Montreal Heart Recent work has focused on the potential role of two Institute and followed the guidelines of the Canadian 1 1 important systems, the Na / H exchanger (NHE1) [13] Council on Animal Care. Twenty-five mongrel dogs and the renin-angiotensin system [14] . There are simi-(weight, 23-40 kg) were initially anesthetized with larities between the histological appearance of tissue from ketamine (5.3 mg / kg, i.v.), diazepam (0.25 mg / kg, i.v.) atria that have been kept in AF for prolonged periods and and halothane (1-2%). Unipolar pacing leads were inchronically-ischemic ventricular myocardium [15] . In addiserted in the right ventricular (RV) apex and the right atrial tion, preliminary data have been presented that point to (RA) appendage under fluoroscopic guidance. The leads reduced atrial blood flow in chronic AF [16] . Strong were connected to a ventricular pacemaker (model 8084 or activation of NHE1 results from the intracellular acidosis 8086, Medtronic) and a custom-modified atrial tachduring acute ischemia [17] , and NHE1 stimulation plays an ypacemaker implanted in a subcutaneous pocket in the important role in arrhythmias associated with acute isneck. AV block was created by radiofrequency catheter 21 chemia [18, 19] , possibly by promoting Ca -loading ablation to avoid excessively rapid ventricular responses [20, 21] . These observations led Jayachandran et al. [13] to during atrial tachypacing, and the RV pacemaker was evaluate the ability of cariporide, an NHE1 inhibitor programmed to capture the ventricles at 80 bpm. The right previously known as HOE642, to prevent atrial tachatrium was stimulated at 400 bpm for 1 week. ycardia-induced remodeling. They found that cariporide Rapidly-paced dogs were treated with 240 mg / day of prevented effective refractory period (ERP) abbreviation cariporide, an NHE1 inhibitor (CariL, n56), 1000 mg / day occurring within 30 min of atrial pacing at 600 bpm, and cariporide (CariH, n56), 2 mg / kg / day enalapril, an ACE concluded that NHE1 might be involved in short-term inhibitor (E, n56), or no drug (ND, n57), beginning 3 tachycardia-induced remodeling.
days before atrial pacemaker activation and continuing Pedersen et al. [22] have shown that the angiotensinuntil the morning of the electrophysiological study. The converting enzyme (ACE) inhibitor trandolapril reduces 240 mg / day dose of cariporide was selected because it is the prevalence of AF after acute myocardial infarction in the highest dose in clinical use. When our initial data patients with left ventricular dysfunction. The mechanism suggested a lack of cariporide effect at this dose, we of this benefit is unknown. Based on their own unpubdecided to study an additional series of dogs (CariH) lished observations that the non-ACE angiotensin-II formexposed to higher doses. To ensure therapeutic concening enzyme chymase is more strongly expressed in the left trations in the high-dose cariporide group, blood samples atrium than in other cardiac chambers, Nakashima et al.
were obtained for subsequent measurement of plasma [14] evaluated the effects on atrial tachycardia-remodeling cariporide concentration at 0, 30, 60 and 90 min after the of blocking angiotensin-1 (AT ) receptors and inhibiting morning dose on the day before electrophysiological study, 1 ACE. They found that atrial tachypacing at 800 bpm prior to the second dose on that day, and at the time of the decreased atrial ERP over 120 min, an effect that could be electrophysiological study. Cariporide concentrations were mimicked by angiotensin-II infusion and could be blocked measured by Aventis Pharma, Frankfurt, Germany. The by the AT -receptor antagonist candesarten as well as the enalapril dose was based on a previous study we conducted 1 ACE inhibitor capropril. in which 2 mg / kg of enalapril produced highly-significant These observations suggest that either NHE1 or ACE reductions in CHF-induced atrial remodeling [24] . Nine inhibition can prevent short-term (,2 h) tachycardia-indogs were used as an unpaced control group, three of duced atrial electrical remodeling. Since NHE1 and ACE which were instrumented and monitored like atrial tachinhibitors are available for clinical development, they ypacing dogs but without pacemaker activation. The could be used for AF therapy if they effectively prevented results in these sham dogs were the same as in six acute remodeling; however, the efficacy of NHE1 and ACE control animals; therefore the results of all nine unpaced inhibitors in longer-term electrical remodeling, as might control dogs were grouped together for analysis purposes. occur with persistent AF, has not been studied. In order to
On study days, dogs were anesthetized with morphine (2 address this issue, we examined the effects of the NHE1 mg / kg, s.c.) and a-chloralose (120 mg / kg, i.v., followed inhibitor cariporide and the ACE inhibitor enalapril on by 29.25 mg / kg / h) and ventilated to maintain physiologiatrial electrophysiological remodeling caused by 7 days of cal arterial blood gases (pH 7.38-7.45, SaO .95%). In artery and both femoral veins were cannulated for pressure wavelength was calculated as the product of local CV and monitoring and drug administration. A median sternotomy local ERP [26] . was performed, and bipolar, Teflon-coated stainless steel Statistical comparisons of multiple group means were electrodes were inserted into the RA and left atrial (LA) obtained by analysis of variance (ANOVA). A t-test with appendages for recording and stimulation. A programBonferroni correction was used to evaluate the significance mable stimulator (Digital Cardiovascular Instruments) was of differences between individual mean values. Average used to deliver 2-ms pulses at twice-threshold current. Five results are given as the mean6S.E.M., and a two-tailed thin silicon plaques containing 240 bipolar electrodes were P,0.05 was considered statistically significant. sewn into position to cover the atrial epicardial surface, and stimulation and recording were performed as previously described [25] .
Results

Changes in properties of AF 2.2. Electrophysiological study
Dogs subjected to 7 days of rapid atrial pacing without The ERP was measured at the LA and the RA appendrug therapy had significantly increased AF duration dages with 15 basic (S1) stimuli at basic cycle lengths (8646364 s, P,0.05) compared to unpaced dogs (BCLs) of 150, 200, 250, 300 and 360 ms, followed by a (129680 s). AF duration of enalapril-treated dogs premature (S2) stimulus, with the ERP defined as the (6456365 s), low-dose cariporide dogs (6096376 s) and longest S1S2 interval failing to produce a response. The high-dose cariporide-treated dogs (7096352 s) were not mean of three ERP values at each BCL was used for data significantly different from no-drug atrial tachypacing analysis. In the case of a $10-ms difference between each dogs. Persistent AF was noted in three of seven (43%) measurement, one or two additional ERP measurements no-drug dogs, two of six (33%) enalapril dogs, two of six were obtained, and the mean of all determinations was (33%) low-dose cariporide dogs and two of six (33%) used. To evaluate regional ERP properties, ERPs were high-dose cariporide dogs vs. none (0%) of unpaced dogs. measured at a BCL of 300 ms at seven sites: RA Fig. 1 shows vulnerability to AF induction by single atrial appendage, RA posterior wall, RA inferior wall, LA premature extrastimuli. A single premature extrastimulus appendage, LA posterior wall, LA inferior wall, and was able to induce AF at 47.9% of sites in no-drug Bachmann's bundle.
tachypaced dogs, 47.9% in enalapril dogs, 33.3% in low-AF was induced by stimulating the atrium with up to dose and 35.4% in high-dose cariporide dogs, with each three consecutive extrastimuli at a BCL of 150 ms and then atrial burst pacing (10 Hz, 2-ms stimuli at four times threshold current for 1-10 s). To obtain an index of AF duration, AF was induced ten times if AF duration was #20 min and five times if AF lasted between 20 and 30 min. AF that lasted .30 min, which was considered persistent, was terminated by DC electrical cardioversion, and 30 min was allowed before the experiment was continued. If persistent AF was induced on two occasions, no further AF inductions were performed. We found that the longest AF period in each dog was the most consistent index of AF duration for each group. The mean duration of longest AF episodes per dog was therefore used as the index of AF duration to characterize each group. Atrial vulnerability was defined as the percentage of sites in each dog at which AF could be induced by single extrastimuli.
Data analysis
Conduction velocity (CV) was determined by analyzing activation at four electrode sites in the direction of rapid propagation. Distance from the proximal site was plotted value in atrial tachypaced dogs significantly greater than in atrial tachycardia-induced remodeling were not due to unpaced dogs (4.2%, P,0.01 for no-drug and enalapril inadequate plasma concentrations. dogs, P,0.05 for each cariporide group; P5NS among all tachypaced groups).
Discussion
Changes in electrophysiological variables
In the present study, we have evaluated the effects of Fig. 2A shows ERP values at various BCLs in the RA inhibiting NHE1 and ACE by oral therapy with enalapril appendage (left) and LA appendage (right) for all groups.
and cariporide on the atrial remodeling induced by 7 days Atrial tachypaced no-drug dogs, enalapril-treated tachof atrial tachypacing. We found that, despite evidence for ypaced dogs, and cariporide-treated tachypaced dogs had benefit from these drugs against short-term remodeling, significantly reduced ERP at all BCLs at either site they have no significant protective effects against the ERP compared to unpaced dogs (P,0.01 for each). All groups reduction, abolition of rate-adaptation, and increases in AF of tachypaced dogs had the ERP changes characteristic of duration and atrial vulnerability produced by a week of atrial tachycardia-induced remodeling in normal hearts as atrial tachycardia. described previously [1-5]: decreased ERP and loss of ERP rate-adaptation. Fig. 2B shows mean CV values in RA (left) and LA (right). These were unaltered in any atrial 4.1. Relationship to previous observations regarding tachypaced group and were consistent with the results of atrial tachycardia-induced remodeling previous studies in the 7-day atrial tachycardia remodeling setting [4] . Wavelength changes in the RA (Fig. 2C, left) Recent studies in animal models and humans have and LA (Fig. 2C, right) largely reflected ERP alterations,
shown that atrial tachycardia (whether as a result of rapid with wavelength significantly decreased in all tachypaced 1:1 pacing or maintained AF) produces shortening of the groups and with no significant differences among groups atrial ERP and loss of physiological ERP rate adaptation treated with different drugs. shown that atrial tachycardia slows conduction in normal Although the degree of remodeling varied among regions, hearts significantly over a 1-week period. In this study, we atrial tachypacing significantly reduced atrial ERP comfound shortening of atrial ERP and loss of ERP rate pared to unpaced controls at all sites in each tachypaced adaptation produced by rapid pacing that parallels previous group. Results were not significant among tachypaced reports in animal models of AF as well as human experigroups. Fig. 3B displays the regional distribution of CV at ments. a BCL of 300 ms. There were small but inconsistent Although the mechanisms underlying atrial tachycardiadifferences among groups and CV was not affected overall.
induced remodeling in normal hearts are incompletely Fig. 3C Verapamil has no effect on ERP or AF vulnerability Mean plasma cariporide levels in high-dose cariporide changes induced by 1 and 6 weeks of atrial tachycardia 21 treated dogs averaged 1.660.3, 2.360.9, 4.661.4, and [12] . Whereas the selective T-type Ca channel blocker 5.961.6 mg / ml at 0, 30, 60 and 90 min after the morning mibefradil protects against atrial remodeling caused by 21 dose on the day before electrophysiological study, 4.860.7 7-day atrial tachycardia, the L-type Ca channel blocker mg / ml prior to the second dose on that day, and 1.560. 4 diltiazem is not effective [10, 11] . These reports indicate mg / ml at the time of the electrophysiological study, that the efficacy of an intervention for remodeling by respectively. All of these concentrations were greater than short-term atrial tachycardia (minutes or hours) does not the concentration (0.55 mg / ml) required for complete necessarily imply efficacy against remodeling induced by NHE1 blockade (Aventis Pharma, unpublished data).
longer durations (.24 h) of atrial tachyarrhythmia. This Therefore, the lack of important effects of cariporide on observation is consistent with evidence that the mecha- 
Effects of ACE and NHE1 inhibition on atrial electrical remodeling and AF
The ACE inhibitor trandolapril has been shown to reduce the occurrence rate of AF in post-myocardial infarction patients with left ventricular dysfunction [22] . The mechanism of AF prevention by this ACE inhibitor is unknown; however, there is evidence for a role of the renin-angiotensin system in clinical AF. Goette et al. [30] have observed increased ACE expression and alterations in angiotensin II receptor expression [31] in atrial tissues of patients with AF. Recently, Nakashima et al. [14] reported that intravenous administration of the ACE inhibitor captopril or the angiotensin II type 1 receptor (AT1) antagonist candesartan prevents the shortening of atrial ERP and loss of ERP rate adaptation caused by 180 min of atrial tachypacing. The results of Nakashima's study suggest that inhibition of atrial tachycardia-induced remodeling could have contributed to the clinical benefits against AF observed with trandolapril. The results of the present study argue that beneficial effects against tachycardia-remodeling are unlikely to be the principal mechanism of ACE inhibitor efficacy in AF. Li et al. [32] have shown that oral enalapril reduces mitogen activated protein kinase activation, atrial fibrosis and AF promotion in a dog model of CHF. This observation provides an alternative explanation for the therapeutic benefits of ACE inhibition in AF: the prevention of atrial structural remodeling.
NHE1 plays a key role in a variety of cardiac injury states, particularly those associated with myocardial ischemia and reperfusion [33] . NHE1 inhibition has been shown to have beneficial effects on myocardial remodeling and CHF after myocardial infarction [34] and to promote conversion of VF in a rat model [35] . Jayachandran et al. [13] showed that the atrial ERP abbreviation and loss of ERP rate adaptation produced by atrial pacing at 600 bpm for 5 h in dogs were prevented by the NHE1 inhibitor HOE642 (cariporide). In addition, acute atrial ischemia produced by right coronary artery occlusion produced shortening of the right atrial ERP and loss of ERP rate adaptation, which were also prevented by NHE1 blockade. These findings were interpreted as pointing to a potential role for NHE1 activation by ischemia in atrial electrical remodeling caused by 5 h of atrial tachypacing. Similarly, cariporide was found to attenuate atrial contractile dysfunction caused by short-term atrial tachycardia [36] . preventing atrial tachycardia remodeling, it would be potentially quite useful in AF. Unfortunately, the results of the present study were disappointing in this regard -no nisms underlying long-term atrial tachycardia-induced benefit against atrial remodeling was observed from remodeling are different from those of short-term remodelcariporide in dogs exposed to 7 days of atrial tachycardia, ing [29] .
even at a dose demonstrated by plasma concentration measurements to maintain effective concentrations of the oxidative enzymes are not altered by AF lasting 1 week or drug at all times.
greater [45] , arguing against a role for atrial ischemia in mediating the effects of long-term atrial tachycardia-in-4.3. Novel findings and potential significance duced remodeling. The concentrations of tissue phosphocreatine decreased by 60% over the first week and normalThis is the first study of which we are aware to evaluate ized by 8 weeks [45] . It is therefore conceivable that the effects of inhibiting NHE1 and ACE on long-term ischemia could play a role in short-term atrial tachycardiaatrial tachycardia-induced remodeling. The results suggest remodeling, with adaptive changes occurring subsequently. that neither NHE1 inhibition nor ACE inhibition alone is Such a scenario might explain why NHE1 blockade seems sufficient to prevent remodeling caused by 7 days of atrial to prevent short-term atrial tachycardia-remodeling but to tachycardia. Although this result is disappointing, the study have no effect on longer-term remodeling. was rigorously performed and it is in many ways just as
The rationale for expecting ACE or AT receptor 1 important to know when interventions do not work as inhibition to antagonize atrial tachycardia remodeling is when they do.
based on the efficacy of ACE inhibition in preventing AF Short-term studies of atrial tachycardia-remodeling are in patients with left ventricular dysfunction post-myocarmuch easier to perform than longer-term studies. There is dial infarction. The studies of Li et al. [32] provide an no need for sterile surgery to implant chronic pacemakers, alternative explanation, the inhibition of structural re-AV block may be unnecessary because the ventricular modeling. The basis for benefit in short-term atrial tachyresponse can be observed directly, and drugs can be given cardia remodeling seen by Nakashima et al. [14] is unclear by intravenous infusion rather than orally. On the other and merits further study. hand, there are important limitations to short-term studies. The administration of bolus intravenous doses of drugs can 4.4. Potential limitations result in plasma concentrations much higher than those achieved clinically, with a significant risk of non-specific
The present study evaluated electrical remodeling ineffects. Short-term atrial tachycardia remodeling (,12 h duced by 7 days of atrial tachycardia. This tachypacing duration) has quite limited AF-promoting action [1, 4] ; duration was selected because ionic remodeling is near therefore, the clinical relevance of preventing short-term steady state after 7 days of tachycardia [23] . Although we remodeling is much less than that of preventing longercannot exclude the possibility that results might have been term tachycardia remodeling. The autonomic state of dogs different for a different tachypacing duration, the absence during the remodeling process is quite abnormal in a of any clear effect in the present study suggests that the short-term open chest model, which may interfere with process of ionic remodeling underlying longer-term atrial signal transduction mechanisms normally involved in atrial tachycardia remodeling was not significantly altered. tachycardia remodeling. In addition, short-term remodeling 21 primarily involves functional changes such as Ca -and i voltage-dependent I inactivation [38, 39] , whereas CaL Acknowledgements longer-term remodeling likely involves changes in ion channel expression due to reduced levels of messenger This work was supported by the Canadian Institutes of RNA encoding ion channel subunits [40] [41] [42] and possibly Health Research (CIHR), the Mathematics of Information post-transcriptional mechanisms as well [43] . These conTechnology and Complex Systems (MITACS) Network of siderations may explain why so many agents, including Centers of Excellence and the Quebec Heart and Stroke verapamil [7] [8] [9] , cariporide [13, 38] , renin-angiotensin Foundation. Kaori Shinagawa is a CIHR fellow. The system inhibitors [14] and even flecainide [44] inhibit authors thank Aventis Pharma, Frankfurt, for providing short-term electrical remodeling, but so few agents are cariporide and for performing the measurements of effective in models of long-term atrial tachycardia-induced cariporide plasma concentrations, Chantal Maltais and remodeling. It is therefore very important that studies of Nathalie L'Heureux for technical assistance, and France agents to prevent atrial tachycardia remodeling not beT heriault for secretarial help with the manuscript. They limited to short-term observations. also thank Merck Laboratories for providing the enalapril The reasons to believe that NHE1 inhibition might be used in these studies. useful in preventing atrial tachycardia-remodeling relate to similarities in histological appearance of fibrillating atrial tissue and chronically ischemic ventricles [15] , preliminary References data suggesting reduced atrial blood flow in AF [16] , and evidence for a role of NHE1 in ventricular arrhythmias 
